Inventiva/$IVA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inventiva
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Ticker
$IVA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
116
ISIN
US46124U1079
Website
Inventiva Metrics
BasicAdvanced
$450M
-
-$3.60
0.61
-
Price and volume
Market cap
$450M
Beta
0.61
52-week high
$4.05
52-week low
$2.67
Average daily volume
26K
Financial strength
Current ratio
0.924
Quick ratio
0.903
Long term debt to equity
-95.626
Total debt to equity
-169.953
Interest coverage (TTM)
-1.13%
Profitability
EBITDA (TTM)
-112.913
Gross margin (TTM)
90.09%
Net profit margin (TTM)
-1,251.10%
Operating margin (TTM)
-662.57%
Effective tax rate (TTM)
-0.17%
Revenue per employee (TTM)
$151,800
Management effectiveness
Return on assets (TTM)
-63.60%
Return on equity (TTM)
265.67%
Valuation
Price to revenue (TTM)
11.752
Price to book
-2.48
Price to tangible book (TTM)
-2.48
Price to free cash flow (TTM)
-2.006
Free cash flow yield (TTM)
-49.85%
Free cash flow per share (TTM)
-168.50%
Growth
Revenue change (TTM)
-38.24%
Earnings per share change (TTM)
26.56%
3-year revenue growth (CAGR)
18.36%
10-year revenue growth (CAGR)
8.64%
3-year earnings per share growth (CAGR)
34.47%
10-year earnings per share growth (CAGR)
15.22%
Inventiva News
AllArticlesVideos
Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
GlobeNewsWire·2 days ago
Inventiva receives $10 million milestone payment from CTTQ
GlobeNewsWire·4 days ago
Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inventiva stock?
Inventiva (IVA) has a market cap of $450M as of July 11, 2025.
What is the P/E ratio for Inventiva stock?
The price to earnings (P/E) ratio for Inventiva (IVA) stock is 0 as of July 11, 2025.
Does Inventiva stock pay dividends?
No, Inventiva (IVA) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Inventiva dividend payment date?
Inventiva (IVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Inventiva?
Inventiva (IVA) has a beta rating of 0.61. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.